Cardiorenal Syndrome in Right Heart Failure Due to Pulmonary Arterial Hypertension—The Right Ventricle as a Therapeutic Target to Improve Renal Function
Cardiovascular Drugs and Therapy · 2025
DOI: 10.1007/s10557-024-07588-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Drugs and Therapy, 2025. Verfasst von Kenzo Ichimura und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Pulmonary, Allergy and Critical Care, Stanford University, 1701 Page Mill Road, Palo Alto, CA, 94304, USA. kennzo…. Hauptthemen laut MEDLINE: Cardio-Renal Syndrome, Ventricular Dysfunction, Right, Ventricular Function, Right, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 100 Literaturangaben. Gefördert von: American Heart Association, NHLBI NIH HHS, U.S. Department of Defense.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Cardiorenal syndrome (CRS) due to right ventricular (RV) failure is a disease entity emerging as a key indicator of morbidity and mortality. The multifactorial aspects of CRS and the left-right ventricular interdependence complicate the link between RV failure and renal function. RV failure has a direct pathophysiological link to renal dysfunction by leading to systemic venous congestion in certain circumstances and low cardiac output in other situations, both leading to impaired renal perfusion. Indeed, renal dysfunction is known to be an independent predictor of mortality in patients with pulmonary arterial hypertension (PAH) and RV failure. Thus, it is important to further understand the interaction between the RV and renal function. RV adaptation is critical to long-term survival in patients with PAH. The RV is also known for its remarkable capacity to recover once the aggravating factor is addressed or mitigated. However, less is known about the renal potential for recovery following the resolution of chronic RV failure. In this review, we provide an overview of the intricate relationship between RV dysfunction and the subsequent development of CRS, with a particular emphasis on PAH. Additionally, we summarize potential RV-targeted therapies and their potential beneficial impact on renal function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Division of Pulmonary, Allergy and Critical Care, Stanford University, 1701 Page Mill Road, Palo Alto, CA, 94304, USA. kennzo@stanford.edu.
- Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford University, Stanford, CA, 94305, USA. kennzo@stanford.edu.
- Cardiovascular Institute, Stanford University, Stanford, CA, 94305, USA. kennzo@stanford.edu.
- Albany Medical College, Albany, NY, 12208, USA.
- Department of Medicine, Loma Linda VA Health Care System, Loma Linda, CA, 92357, USA.
- Division of Nephrology, Department of Medicine, Albany Medical College, Albany, NY, 12208, USA.
ORCID-Profile: Kenzo Ichimura
Förderung
- American Heart Association
- NHLBI NIH HHS
- U.S. Department of Defense
- Stanford Cardiovascular Institute, School of Medicine, Stanford University
- National Heart, Lung, and Blood Institute
Zitieren
APA
Ichimura, K., Gross, A., Mathew, R. O., Salman, L., Reddy, S., Spiekerkoetter, E., & Sidhu, M. S. (2025). Cardiorenal Syndrome in Right Heart Failure Due to Pulmonary Arterial Hypertension—The Right Ventricle as a Therapeutic Target to Improve Renal Function. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-024-07588-8
Vancouver
Ichimura K, Gross A, Mathew RO, Salman L, Reddy S, Spiekerkoetter E, et al. Cardiorenal Syndrome in Right Heart Failure Due to Pulmonary Arterial Hypertension—The Right Ventricle as a Therapeutic Target to Improve Renal Function. Cardiovascular Drugs and Therapy. 2025. doi:10.1007/s10557-024-07588-8
BibTeX
@article{Ichimura2025,
author = {Ichimura, Kenzo and Gross, Adam and Mathew, Roy O and Salman, Loay and Reddy, Sushma and Spiekerkoetter, Edda and Sidhu, Mandeep S},
title = {Cardiorenal Syndrome in Right Heart Failure Due to Pulmonary Arterial Hypertension—The Right Ventricle as a Therapeutic Target to Improve Renal Function},
journal = {Cardiovascular Drugs and Therapy},
year = {2025},
doi = {10.1007/s10557-024-07588-8}
}
EUVIMED